In a study of radioresistant and radiosensitive cervical cancer, it was found that after irradiation, patients with BAX-positive tumors showed a significantly better response compared to patients with BAX-negative tumors, whereas patients with BCL2-positive tumors showed a significantly weaker response compared to patients with BCL2-negative tumors; increased BAX expression after radiation therapy correlated with good survival, while increased BCL2 expression correlated with poor survival. The gene discussed is BAX; the disease is cervical carcinoma.